New hope for Tough-to-Treat lymphoma: experimental combo trial opens
NCT ID NCT06743503
First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 21 times
Summary
This early-stage study tests an experimental drug (UB-VV400) alone and with rapamycin in adults with aggressive B-cell lymphoma that has returned or not responded to treatment. About 70 participants will receive the therapy to find the safest dose and check for side effects. The goal is to offer a new option for patients who have limited choices, including those who have already tried CAR T-cell therapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences
NOT_YET_RECRUITINGTianjin, China
Contact
Contact
-
The First Affiliated Hospital of Nanjing Medical University
RECRUITINGNanjing, China
Contact
Conditions
Explore the condition pages connected to this study.